RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

In a conversation I had last year with a Big Pharma BusDev group about Cortex, they referred to the "fragmented" Ampakine rights with a tone of complete dismay.

Isn't this a pretty compelling argument against the overall corx indication-based outlicencing strategy?

I've long advocated for an across-the-board low-impact outlicencing strategy, in exchange for good upfronts and royalties. This would stabilize corx's bottom line, and would allow it to focus on high-impact development.

Following the current strategy, each outlicencing deal makes subsequent deals less attractive, since they confront prospective partners with a fragmented IP.